Contact
searchSearch
HMP Global
Login

Lymphoma (ASH 2024) Basic Listing

Updates in Lymphoma
From the ASH Annual Meeting & Exposition

Adam Olszewski, MD
Videos
Mosunetuzumab Plus Polatuzumab Vedotin Shows Improved Outcomes vs Rituximab Plus Polatuzumab Vedotin Among Patients With R/R Large B-Cell Lymphoma
01/06/2025
Subcutaenous mosunetuzumab plus polatuzumab vedotin demonstrates improved efficacy and response rates compared with rituximab plus polatuzumab vedotin for patients with relapsed/refractory (R/R) LBCL, according to phase 2 study results...
Subcutaenous mosunetuzumab plus polatuzumab vedotin demonstrates improved efficacy and response rates compared with rituximab plus polatuzumab vedotin for patients with relapsed/refractory (R/R) LBCL, according to phase 2 study results...
Subcutaenous mosunetuzumab plus...
01/06/2025
Oncology
Elizabeth Brem, MD, University of California, Irvine
Videos
Odronextamab Monotherapy vs Standard of Care Therapy for Follicular Lymphoma: OLYMPIA-1 Trial
12/16/2024
Elizabeth Brem, MD, discusses safety and preliminary efficacy results from the phase 3 OLYMPIA-1 trial exploring odronextamab monotherapy for patients with high-risk follicular lymphoma.
Elizabeth Brem, MD, discusses safety and preliminary efficacy results from the phase 3 OLYMPIA-1 trial exploring odronextamab monotherapy for patients with high-risk follicular lymphoma.
Elizabeth Brem, MD, discusses...
12/16/2024
Oncology
John Burke, MD
Conference Coverage
First-Line Subcutaneous Mosunetuzumab Shows Encouraging Efficacy, Manageable Safety for Patients With Low Tumor Burden Follicular Lymphoma
12/13/2024
According to updated results presented by John Burke, MD, at the 66th ASH Annual Meeting, frontline subcutaneous treatment with fixed-duration mosunetuzumab among patients with low-tumor burden FL demonstrated efficacy and safety.
According to updated results presented by John Burke, MD, at the 66th ASH Annual Meeting, frontline subcutaneous treatment with fixed-duration mosunetuzumab among patients with low-tumor burden FL demonstrated efficacy and safety.
According to updated results...
12/13/2024
Oncology
Anne Marijn Kramer, MD, PhD
Videos
CD22-Directed CAR-T Therapy Demonstrates Durable Remissions for Patients With Large B-Cell Lymphomas Relapsing After CD19-Directed CAR-T Therapy
12/08/2024
Anne Marijn Kramer, MD, PhD, discusses follow-up data from a phase 1 trial showing that CD22-directed CAR-T therapy provides durable remissions and long-term survival after 3 years for patients with large B-cell lymphomas progressing after...
Anne Marijn Kramer, MD, PhD, discusses follow-up data from a phase 1 trial showing that CD22-directed CAR-T therapy provides durable remissions and long-term survival after 3 years for patients with large B-cell lymphomas progressing after...
Anne Marijn Kramer, MD, PhD,...
12/08/2024
Oncology
Tycel Phillips, MD
Conference Coverage
Analyzing Response Rate and Line of Therapy Correlation Among Patients With R/R Follicular Lymphoma
12/10/2023
At the 65th ASH Annual Meeting, Tycel Phillips, MD, discusses the relationship between the line of treatment, treatment site, and response rates among patients with follicular lymphoma with a poor prognosis, according to findings from a...
At the 65th ASH Annual Meeting, Tycel Phillips, MD, discusses the relationship between the line of treatment, treatment site, and response rates among patients with follicular lymphoma with a poor prognosis, according to findings from a...
At the 65th ASH Annual Meeting,...
12/10/2023
Oncology
Conference Coverage
Epcoritamab Plus Rituximab and Lenalidomide Yields High Complete Metabolic Response Rate in Follicular Lymphoma
12/16/2022
In patients with relapsed or refractory follicular lymphoma, epcoritamab combined with rituximab and lenalidomide demonstrated manageable safety and a high complete metabolic response rate, according to findings from a phase 1/2 study.
In patients with relapsed or refractory follicular lymphoma, epcoritamab combined with rituximab and lenalidomide demonstrated manageable safety and a high complete metabolic response rate, according to findings from a phase 1/2 study.
In patients with relapsed or...
12/16/2022
Oncology
Conference Coverage
Epcoritamab With Rituximab Plus Lenalidomide Demonstrates Promising Efficacy as First-Line Therapy for Patients With Follicular Lymphoma
12/16/2022
Epcoritamab combined with rituximab plus lenalidomide regimen showed encouraging efficacy as a first-line treatment for follicular lymphoma, according to data presented at the 2022 American Society of Hematology Annual Meeting and Exposition.
Epcoritamab combined with rituximab plus lenalidomide regimen showed encouraging efficacy as a first-line treatment for follicular lymphoma, according to data presented at the 2022 American Society of Hematology Annual Meeting and Exposition.
Epcoritamab combined with...
12/16/2022
Oncology
Conference Coverage
Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine for Treatment of Patients With R/R Follicular Lymphoma
12/16/2022
Usage of regimens of lenalidomide-rituximab or lenalidomide-rituximab-bendamustine were associated with less severe toxicity than expected in patients with R/R FL, according to analysis of a phase 2 trial.
Usage of regimens of lenalidomide-rituximab or lenalidomide-rituximab-bendamustine were associated with less severe toxicity than expected in patients with R/R FL, according to analysis of a phase 2 trial.
Usage of regimens of...
12/16/2022
Oncology
Conference Coverage
Rituximab Monotherapy Prolongs Time to Next Treatment in Low Tumor Burden Follicular Lymphoma
12/12/2022
Long-term findings from the phase 3 Watch & Wait trial show that after a median follow-up of 12.3 years, rituximab is highly effective at delaying time to next treatment in patients with low tumor burden follicular lymphoma.
Long-term findings from the phase 3 Watch & Wait trial show that after a median follow-up of 12.3 years, rituximab is highly effective at delaying time to next treatment in patients with low tumor burden follicular lymphoma.
Long-term findings from the...
12/12/2022
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use